A United Nations-led meeting held in Qatar with the Taliban on increasing engagement with Afghanistan does not translate into a recognition of their government, a U.N. official said Monday.

The gathering on Sunday and Monday in Qatar's capital of Doha with envoys from some two dozen countries was the first time that representatives of the Afghan Taliban administration attended such a U.N.-sponsored meeting.

The Taliban were not invited to the first meeting, and U.N. Secretary-General António Guterres said they set unacceptable conditions for attending the second one, in February, including demands that Afghan civil society members be excluded from the talks and that the Taliban be treated as the country’s legitimate rulers.

NO AFGHAN WOMEN ALLOWED TO ATTEND UN-LED MEETINGS WITH TALIBAN: 'CAVING TO TERRORIST DEMANDS'

Ahead of Doha, representatives of Afghan women were excluded from attending, paving the way for the Taliban to send their envoys — though the organizers insisted that demands for women’s rights would be raised.

"I would like to emphasize that this meeting and this process of engagement does not mean normalization or recognition," Rosemary A. DiCarlo, a U.N. official for political and peacebuilding affairs said Monday.

"My hope is that the constructive exchanges on the various issues over the last two days have moved us a little closer to resolving some of the problems that are having such a devastating impact on the Afghan people," she added.

Zabihullah Mujahid, chief Taliban government spokesman who headed the delegation to Doha, said there was opportunity for them to meet with representatives of various countries on the sidelines of the gathering.

He added that the messages from the Taliban "reached all participating" countries at the meeting. Afghanistan needs cooperation with the private sector and in the fight against drugs, he also said. "Most countries expressed their willingness to cooperate in these areas."

The Taliban seized power in August 2021 as United States and NATO forces were in the final weeks of their pullout from Afghanistan following two decades of war. No country officially recognizes the Taliban and the U.N. has said that recognition remains practically impossible while bans on female education and employment remain in place.

However, some participants, including Canada, expressed disappointment over the exclusion of women and civil society representatives.

"Canada is extremely disappointed that the U.N. organizers have excluded non-Taliban Afghan participants, including women’s advocates, religious and ethnic minorities, and human rights groups from participating in the meeting’s main sessions," David Sproule, Canada’s special representative for Afghanistan, said in a statement.

DiCarlo, the U.N. official, said that "while women and civil society were not sitting across the table form the de facto (Taliban) authorities in last two days, we made their voices heard ... civil society has a rightful role to play in shaping Afghanistan’s future."

Two brands of potassium chloride capsules are being recalled because they may not dissolve as they should, which could cause a person to have a heart attack, according to the Food and Drug Administration (FDA).

In a press release published on June 25, the FDA explained that Glenmark Pharmaceuticals Inc. is recalling 114 batches of a product called Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K. The reason is because of "failed dissolution" in the pills.

The product is intended for patients who suffer from low potassium levels, or hypokalemia. 

According to the FDA, the failed dissolution could elevate consumers' potassium to the point where a heart attack is possible.

VIRAL HOSTAGE TAPE SLEEPING TREND GAINS STEAM AS DOCTORS WARN OF POTENTIAL DANGERS

American Health Packaging issued a similar recall of 21 batches of the same capsules. The capsules were also made by Glenmark but distributed by BluePoint Laboratories.

"The failed dissolution of potassium chloride extended release capsules may cause high potassium levels, also known as hyperkalemia, which can result in irregular heart beat that can lead to cardiac arrest," the FDA's statement read. 

"For patients who require chronic use of potassium chloride extended-release oral capsules… there is a reasonable probability of developing hyperkalemia that may lead to a range of severity of adverse events from being asymptomatic to more severe potential life-threatening adverse events of hyperkalemia such as cardiac arrythmias, severe muscle weakness, and death," the agency added.

MORE AMERICANS SMOKE MARIJUANA DAILY THAN DRINK ALCOHOL, STUDY CLAIMS

The FDA also noted that there have not been any hyperkalemia cases or "serious adverse events" reported related to the product yet. The statement noted that the capsules are sold in bottles of 100-count and 500-count.

"Glenmark is notifying its wholesale and distributor customers by written letters and is arranging for return of all recalled batches," the FDA said. "Wholesalers, distributors, and retailers that have the recalled products should discontinue distribution of the recalled product lots immediately and follow the instructions provided in the written recall letter."

"Wholesalers and distributors should conduct a sub-recall to retail or pharmacy customers."

Fox News Digital reached out to Glenmark Pharmaceuticals Inc. for comment, but did not hear back.